Literature DB >> 20498826

The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Dwight D Kloth, Lew Iacovelli, Rebecca Arbuckle, Angela C McIntosh.   

Abstract

Entities:  

Year:  2010        PMID： 20498826      PMCID： PMC2873720     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  52 in total

Review 1.  Nondermatologic adverse events associated with anti-EGFR therapy.

Authors:  Alan B Sandler
Journal:  Oncology (Williston Park)       Date:  2006-04       Impact factor: 2.990

Review 2.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

Authors:  Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern
Journal:  J Am Acad Dermatol       Date:  2006-10       Impact factor: 11.527

3.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

Review 4.  A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.

Authors:  Keunchil Park; Koichi Goto
Journal:  Curr Med Res Opin       Date:  2006-03       Impact factor: 2.580

5.  Successful administration of panitumumab alone after severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer.

Authors:  Thomas H Cartwright; Renee Genther
Journal:  Clin Colorectal Cancer       Date:  2008-05       Impact factor: 4.481

Review 6.  Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Authors:  Haiyi Jiang
Journal:  Jpn J Clin Oncol       Date:  2008-12-16       Impact factor: 3.019

7.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

Review 8.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Authors:  Aleix Prat; José Baselga
Journal:  Nat Clin Pract Oncol       Date:  2008-07-08

9.  High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history.

Authors:  Bert H O'Neil; Robert Allen; David R Spigel; Thomas E Stinchcombe; Dominic T Moore; Jordan D Berlin; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

Authors:  F Cappuzzo; G Finocchiaro; E Rossi; P A Jänne; C Carnaghi; C Calandri; K Bencardino; C Ligorio; F Ciardiello; T Pressiani; A Destro; M Roncalli; L Crino; W A Franklin; A Santoro; M Varella-Garcia
Journal:  Ann Oncol       Date:  2007-10-31       Impact factor: 32.976
View more
  1 in total

1.  Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database.

Authors:  Lei Chen; Jacqueline Brown; Dale Quentin Marmaduke; Carlos Mayo; Gerrit Grau; Yiu-Keung Lau; Coleman K Obasaju
Journal:  Support Care Cancer       Date:  2018-02-08       Impact factor: 3.603
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.